Loading…
For statin-myalgia and for heart-failure: targeted yes. For general longevity: limited evidence.
CoQ10 has indication-specific data; healthspan benefits in healthy adults are not well-supported.
Our read is Limited Research. The mechanistic story is plausible and the early signals are interesting, but the human outcome data is thin: a limited evidence base (42/100) and only a divided field (46% consensus). At $20/month, taking CoQ10 is a bet on preliminary science rather than a settled recommendation.
Pulled the public claims about taking CoQ10 from proponents on file (a tracked voice) and weighed them against the more cautious voices (a tracked voice), then cross-checked each against the primary trial and cohort literature and the prevailing clinical guidance. We grade the claim against what the human evidence actually supports, not against how confidently it is stated.
Downside risk on taking CoQ10 is low at sensible doses, but low risk is not no risk: individual response varies, and a low-risk intervention is still only worth it if the benefit is real.
A well-designed human outcome trial — the kind that currently does not exist — demonstrating benefit at the doses people actually use.
The intervention improves the primary outcome at standard doses in healthy adults.
Benefits hold across the populations where it's been tested.
Mechanistic and trial evidence converge on a real, replicable effect.
Benefits hold across the populations where it's been tested.
The intervention improves the primary outcome at standard doses in healthy adults.
Confounding and publication bias inflate the apparent benefit.
Most of the support comes from short or small studies.
Confounding and publication bias inflate the apparent benefit.
Most of the support comes from short or small studies.
Confounding and publication bias inflate the apparent benefit.